Company: CERO
Filing Date: 2025-02-05
Form Type: S-1/A
Source: 0001213900-25-010230
Chunk: 17

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-05
Form: S-1/A
Chunk 17
---
 largely been active in hematological B cell malignancies, we believe CER-1236 will be efficacious in both hematological malignancies and solid tumors. Recent Developments Keystone Equity Financing In February 2024, we entered into a common stock purchase agreement (the “Old Keystone Purchase Agreement”) with Keystone, pursuant to which we may sell and issue, and Keystone is obligated to purchase, up to $25,000,000 of shares of Common Stock (the “Keystone Purchase Shares”); provided that the number of shares issued pursuant to the Old Keystone Purchase Agreement shall not exceed 250,000 shares (the “Initial Limit”). As consideration for Keystone’s commitment to purchase shares of Common Stock pursuant to the Keystone Purchase Agreements, we issued an aggregate of 19,833 shares of Common Stock to Keystone (the “Keystone Commitment Shares”). We previously filed a registration statement on Form S-1 (File No. 333-278603), which was declared effective by the SEC on May 1, 2024, and remains in effect (the “Prior Registration Statement”), with respect to up to (i) 250,000 Keystone Purchase Shares and (ii) 6,191 Keystone Commitment Shares. In November 2024, in order to enable us to issue and sell additional shares in excess of the Initial Limit and up to $25,000,000, we entered into the New Keystone Purchase Agreement with Keystone, pursuant to which we may issue and sell up to $20,589,384 of shares of Common Stock. Through January 8, 2025, we issued 408,683 shares of common stock for net proceeds of $2,273,794 pursuant to the New Keystone Purchase Agreement. As of the date of this prospectus, we have issued and sold 644,966 shares of Common Stock for aggregate proceeds of $5,902,814 under the Keystone Equity Financings (the Old Keystone Purchase Agreement and New Keyston Purchase Agreement). We do not have a right to commence any sales of Common Stock to Keystone under the New Keystone Purchase Agreement until the time when all of the conditions to our right to commence sales of Common Stock to Keystone set forth in the New Keystone Purchase Agreement have been satisfied, including the effectiveness of the registration statement of which this prospectus forms a part. We will control the timing and amount of any sales of Common Stock to Keystone. Actual sales of shares of Common Stock to Keystone under the Keystone Purchase Agreements will depend on a variety of factors to